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Abstract
Mutagens can be carcinogens, and traditionally, they have been identified in vitro using the 
Salmonella ‘Ames’ reverse mutation assay. However, prokaryotic DNA packaging, replication 
and repair systems are mechanistically very different to those in the humans we inevitably 
seek to protect. Therefore, for many years, mammalian cell line genotoxicity assays that can 
detect eukaryotic mutagens as well as clastogens and aneugens have been used. The apparent 
lack of specificity in these largely rodent systems, due partly to their mutant p53 status, has 
contributed to the use of animal studies to resolve data conflicts. Recently, silencing mutations 
at the PIG-A locus have been demonstrated to prevent glycophosphatidylinositol (GPI) 
anchor synthesis and consequentially result in loss of GPI-anchored proteins from the cell’s 
extracellular surface. The successful exploitation of this mutant phenotype in animal studies 
has triggered interest in the development of an analogous in vitro PIG-A mutation screening 
assay. This article describes the development of a robust assay design using metabolically 
active human cells. The assay includes viability and cell membrane integrity assessment and 
conforms to the future ideas of the 21st-century toxicology testing.
Introduction
Genetic toxicology plays an essential role within hazard identification 
and risk assessment during the development of novel drugs as well as 
pesticides, herbicides, flavours, and fragrances. Throughout the early 
stage drug development, a substance’s ability to damage DNA through 
genotoxic mechanisms must be fully investigated to enable accurate and 
cost-effective hazard and risk assessment (1). If possible, this would be 
completed with more emphasis on high content, high throughput in 
vitro genotoxicity assessment, reducing animal usage. Short falls in in 
silico pharmacokinetic and dynamic modelling (2)] as well as report-
edly poor in vitro specificity in carcinogenicity prediction (3) have pro-
duced a battery of in vitro and in vivo genotoxicity assays developed to 
identify potential mutagens, aneugens and clastogens (4,5), which could 
benefit from a broader revision to include 21st-century approaches.
Several regulatory-accepted in vitro mammalian cell muta-
tion assays are available to assess chemically induced gene muta-
tion. These use cell lines derived from mice (L5178Y) and hamster 
(CHO, AS52 and V79), which are often p53 mutant, and humans 
(TK6) (6). The most commonly used genetic endpoints are mutation 
at the thymidine kinase (TK) and hypoxanthine–guanine phospho-
ribosyl transferase (HPRT) loci. Whilst data from the HPRT and 
TK mutation tests are widely accepted in hazard and risk assess-
ment (6), they are relatively time-consuming (3–6 weeks) and highly 
labour-intensive, particularly when characterising dose–response 
relationships, and reportedly have poor specificity (3) that can limit 
their utility in a screening context. However, specificity issues are 
being addressed by a more recent focus on p53 competent human 
cell lines within in vitro Organisation for Economic Cooperation 
and Development (OECD) guidance documents (7). To date, in vivo 
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gene mutation experiments have been restricted largely to transgenic 
models (MutaMouse™ and BigBlue). As these are more expensive 
than inbred animals, they are only used in a regulatory setting as a 
study of ‘last resort’, addressing specific concerns about a potential 
mutagenic signal (identified in vitro) and/or mechanism.
Recently, a novel gene mutation assay based on the endogenous 
phosphatidylinositol–glycan biosynthesis class-A (PIG-A) gene 
(8), located on the p arm of the X-chromosome (9) was developed 
in rodents (10). PIG-A encodes an enzyme critical to the synthe-
sis of glycophosphatidylinositol (GPI) anchor molecules (11,12). 
Specifically, PIG-A is essential in the production of a catalytic subu-
nit of the N-acetylglucosamine transferase complex (13), and com-
bined with numerous other PIG-gene products, pig-b, pig-c etc., it 
contributes to the synthesis of the final branched glycan structure 
of the anchor. This eventually resides on the external surface of the 
cellular membrane, extending into the extracellular space, tethering 
cell-specific and conserved surface antigens (14). Whilst silencing 
mutations in any of these genes may prevent GPI anchor synthe-
sis (15,16), a mutational silencing event within PIG-A is believed 
to be the most common cause of GPI anchor synthesis disruption, 
because it is X-linked (17), and a single mutation can result in a 
deficiency of GPI-anchored cell surface antigens. Hence, the GPI 
anchor-deficient phenotype is generally attributed to PIG-A muta-
tion (18). The mutant genotype (PIG-A−) is also a characteristic of 
patients with paroxysmal–nocturnal–haemoglobinuria (PNH) (19), 
and diagnostic methods have been developed to detect and quan-
tify cells carrying presumptive mutations at the PIG-A locus using 
flow cytometry (FCM) (20). The phenotype is reported to be growth 
neutral in vivo (21), an important factor in mutagenesis studies as it 
avoids mutational bias. Mutant frequency (f) and mutation rate (µ) 
at the PIG-A locus can be measured indirectly, using FCM, record-
ing the loss of expression of specific GPI-anchored cellular antigens 
following mutagen exposure (20,22). The assay potentially has great 
transferability between mammalian species, due to the highly con-
served nature of GPI-anchor synthesis (23).
The development of the rodent erythrocytic in vivo Pig-a gene 
mutation assay has gathered significant momentum, benefitting from 
extensive coordinated ring trials (24–27), methods to support assay 
transfer across mammalian species (21,23,28–34) and high through-
put optimisation (29). In addition, there has been some progress in 
demonstrating the mechanistic basis of the assay (32,35,36), and 
efforts are going on to further characterise the assay in terms of gen-
otoxic mechanisms (37,38) and chemical space. It is hoped that these 
activities will support the development of an OECD guideline in due 
course. Following recent European Union reforms to limit and/or 
ban animal testing (39), especially relevant to the cosmetics and con-
sumer industries (40,41), there has been increased focus on replacing 
animal testing with novel approaches to quantify genotoxic hazard 
for human risk assessment purposes. Innovative technologies are 
being developed to enable high throughout, high content screening 
whilst retaining a high level of sensitivity (42–45).
As part of these efforts, our laboratories have focused efforts on 
the development of an in vitro PIG-A assay design that could be 
used within a screening or a regulatory setting and serve as a pre-
dictive counterpart to the in vivo assay described above. TK6 was 
initially proposed as the cell line of choice based on the following cri-
teria: (i) a non-adherent cell line of haemopoetic origin and short cell 
cycle time to allow short experimental duration; (ii) a cell line with a 
proven track record of high sensitivity and specificity in genotoxicity 
assays; and (iii) a cell line of human origin (with functional p53) to 
improve risk assessment, species specificity, and with the potential 
for future in vitro to human extrapolation. This decision was further 
supported by a recent review of cell lines used in genotoxicity test-
ing, which had preferentially highlighted the benefits of TK6 cells 
(46–48). Other laboratories have described the development of an 
analogous in vitro PIG-O assay in DT40 chicken cells (49) and an 
analogous in vitro PIG-A assay in TK6 cells (42). These assays theo-
retically provide the means for more extensive mechanistic valida-
tion (38), though for wide acceptance, the phenotypic data will need 
DNA sequence data to unambiguously link phenotype to genotype.
This study reports development of a PIG-A mutation assay 
in human B-lymphoblastoid cell lines. The aim was to establish a 
robust assay platform that takes into account the potential limita-
tions of the system. Initially, enrichment techniques were evaluated 
to enable the assessment of GPI anchor surface proteins CD59 and 
CD55 (see supplementary data, available at Mutagenesis Online) as 
potential reporters of phenotypic PIG-A mutation. The need for this 
reflects early findings that the prevalence of the loss of GPI anchor 
phenotype in TK6 cells was very much higher than the expected 
mutation frequency. In addition, aerolysin sensitivity was used to 
validate PIG-A phenotype and was also explored as a potential 
basis for mutant selection, useful in tying phenotype to genotype. 
Dose–response data were generated throughout and were used to 
investigate the sensitivity of the current PIG-A assay design to both 
genotoxic and non-genotoxic compounds, with confocal microscopy 
utilised to provide additional molecular confidence in the phenotype. 
Throughout development, the assay design incorporated viability 
assessments, comprehensive gating strategies as well as a marker for 
non-GPI–associated cell surface protein markers, a potential source 
of misleading results. During the course of the study, the alterna-
tive, metabolically active human MCL-5 cells were found to provide 
a lower background spontaneous mutant prevalence. These assay 
design advancements with the associated flow cytometric gating 
strategies suggest development of an improved assay platform and 
the basis for further optimisation and validation.
Materials and methods
Cell culture
The TK6 cell line was obtained from the American Type Culture 
Collection (ATCC; http://www.atcc.org/). Low passage TK6 cells 
were obtained from Masamitsu Homna (NIH, Japan). AHH-1 and 
MCL-5 cell lines were purchased from Gentest Corporation (now 
BD Biosciences, Oxford, UK). TK6, AHH-1 and MCL-5 cells were 
cultured in 89% RPMI 1640, 1% l-glutamine (Gibco®, Paisley, 
UK) and 10% horse serum (BioSer, Sussex, UK): MCL-5 culture 
media were supplemented with 50 mg/mL Hygromycin B (Merck, 
Hoddesdon, UK). Low passage TK6 growth medium consisted of 
89% RPMI 1640, 1% penicillin–streptomycin (Gibco®, Paisley, UK) 
and 10% heat-inactivated horse serum (cat no. 26050-088, Gibco). 
All cultures were kept within a controlled carbon dioxide (CO2; 
5 ± 1%) incubator maintained at 37.5°C. Prior to use, cryovials of 
human lymphoblastoid TK6, low passage TK6, MCL-5 and AHH-1 
cells were removed from cryopreservation, thawed quickly and cul-
tured under standard conditions. All cell lines were monitored regu-
larly to detect signs of contamination (microscopy) or morphological 
abnormalities and subcultured once prior to the experimental start 
date to ensure reproducible growth dynamics. Stock cell cultures 
were vitally maintained between 105 and 106 cells/mL in 75 cm2 cul-
ture flasks by routine subculturing, with an exception of the TK6 
cell line, which was able to grow consistently from a 4 × 105 cells/
mL seeding concentration. Populations depleted of PIG-A mutant 
cells were cryopreserved and stored in liquid nitrogen for a period 
of up to 6 months. To revive cells from cryogenic storage, they were 
2 B. J. Rees et al.
 at Sw
ansea U
niversity on January 11, 2017
http://m
utage.oxfordjournals.org/
D
ow
nloaded from
 
thawed and cultured for a period of at least 72 h prior to use. Where 
appropriate, the use of fluorescently labelled isotype control anti-
body samples were utilised in order to determine the nature of cell 
line-specific antibody binding, thereby reporting accuracy.
Enrichment strategies to optimise CD59 expression 
within TK6 cells
Dynabead® magnetic bead retrieval 
A mouse anti-human CD59 antibody (cat no.  555761, BD 
Pharmingen™, San Jose, CA, USA) was biotinylated (DSB-X™ 
Biotin Protein Labelling Kit, cat no. D-20655, Molecular Probes, 
Life™ Technologies, Paisley, UK) and used with the Dynabeads® 
Flow Comp™ Flexi Kit (cat no. 11061D, Molecular Probes, Life™ 
Technologies, Paisley, UK) to select cells expressing CD59, i.e. the 
cells with a PIG-A wild-type phenotype. Briefly, 5  ×  107 TK6 cells 
were resuspended in 500 µL of 2–8°C isolation buffer and 25 µL of 
DSB-X™ biotin-labelled antibody, mixed well and incubated at 2–8°C 
(protected from light) for 10 min. Cells were then washed (2 mL cold 
isolation buffer), collected by centrifugation (350 × g for 8 min) and 
the supernatants aspirated prior to resuspension in 1 mL cold isola-
tion buffer and the addition of 75 µL Flow Comp™ Dynabeads®. 
Following mixing, the suspension was incubated for 15 min (2–8°C, 
rolling and tilting), then transferred into a 2-mL microcentrifuge tube 
and placed on a magnetic rack (Qiagen) for 2 min. Following removal 
of the supernatant, the tube was then detached from the magnet and 
the pellet of bead-bound cells was washed, followed by resuspension 
in 1 mL of cold isolation buffer and then re-pelleted (twice). The bead-
bound cells were then resuspended in 1 mL of Flow Comp™ release 
buffer for 10 min (25°C under rolling and tilting) and then placed on 
the magnetic rack for 2 min. The supernatant containing the bead-free 
cells was transferred into a new tube and placed on the magnetic rack 
for an additional 2 min to remove any residual Dynabeads®. Finally, 
the supernatant was centrifuged (350 × g for 8 min), and the resulting 
enriched population of cells expressing CD59 was transferred to a 25 
cm2 cell flask for culture. Quality assurance (QA) FCM based on the 
PIG-A assay was used to determine the level of CD59 enrichment in 
the cell culture (106 cells were removed and stained, see Determination 
of PIG-A mutant frequency using the CD59 phenotypic marker fol-
lowing exposure to the potent mutagen EMS, to determine the fre-
quency of CD59-positive cells, i.e. a PIG-A wild-type phenotype).
Clonal expansion
Cultures were established from cryopreserved TK6 cell stocks and 
analysed using FCM to determine the proportion of cells expressing 
the CD59 antigen, by means of the anti-human CD59-R-PE–labelled 
antibody. >10  ×  106 cells were then harvested by centrifugation 
(250 × g for 7 min) and resuspended to a final concentration of 200 
cells/mL prior to clonal expansion as follows: 100 μL cellular sam-
ples were transferred into each well of six identical 96 well plates 
(Greiner–Bio-One, Gloucestershire, UK), and following 72 h incu-
bation, each well was inverted microscopically assessed for colony 
formation. From these plates, a total of 144 deemed well-established 
colonies were transferred into six 24-well plates, with the addition 
of fresh growth medium (~300 µL), and the cells were cultured for 
a further 72 h. The 10 largest colonies (excess of ~1000 cells) were 
transferred into separate sterile 25 cm2 flasks and cultured to con-
fluency (~1–7  ×  105 cells/mL) within pre-warmed culture media. 
Samples were subsequently analysed for CD59 expression by FCM, 
and the cultures with the resulting highest frequency of cells express-
ing CD59 were prepared for long-term cryopreservation.
Fluorescence-activated cell sorting
A fresh vial of TK6 cells homologous to the cultures used for the 
clonal expansion experimentation, subcultured from the original 
TK6 cell stock, were analysed for CD59 surface antigen expression 
using anti-human CD59-R-PE labelling as well as human leucocyte 
antigen–antigen DR (HLA-DR) presence utilising an anti HLA-DR 
fluorescein isothiocyanate (FITC) antibody and subsequent FCM. 
Approximately 20 000 cells that were CD59-positive and displayed 
uniform HLA-DR fluorescence were isolated using fluorescence-acti-
vated cell sorting (FACS; sorting on a FACSAria 1, BD Biosciences, 
UK). The recovered cells were pooled into 5 mL sorting tubes (BD 
Biosciences, Hertfordshire, UK) within culture medium, pelleted and 
cultured in fresh culture media within 25 cm2 culture flasks prior to 
long-term cryopreservation. Once more QA FCM analysis was per-
formed to confirm the frequency of CD59-positive cells, i.e. a PIG-A 
wild-type phenotype following enrichment and prior to preservation.
Determination of PIG-A mutant frequency using the 
CD59 phenotypic marker following exposure to the 
potent mutagen EMS
For this purpose, 2 × 106 clonally enriched TK6 cells for CD59-
positive expression (see Enrichment strategies to optimise CD59 
expression within TK6 cells–Clonal expansion) were thawed and 
cultured under standard conditions. Following sufficient growth, 
105 cells/mL were seeded into 12.5 cm2 culture flasks and treated 
with either vehicle [dimethyl sulphoxide (DMSO) 1% v/v] or ethyl-
methane sulfonate (EMS; 0–10 µg/mL) for 24 h at 37°C, 5% CO2. 
Following treatment, the cells were washed [10 mL phosphate-buff-
ered saline (PBS)] and cell density determined (Beckman Coulter Z1 
Particle Counter). Then, 106 cells were removed, washed (10 mL 
PBS) and centrifuged (250  × g for 7  min) prior to resuspension 
in 50 µL of fresh RPMI-based culture medium (see Cell culture). 
Simultaneously, parental-treated cell cultures were subcultured to 
105 cells/mL and incubated for a further 24 h to enable subsequent 
daily PIG-A mutation assessments, only if suitable population 
growth has occurred to enable this (>2 × 105 cells/mL). The resus-
pended cellular samples were then incubated with 20 µL (0.1 mg/
mL) of anti-human CD59 PE antibody for 20–30  min at 2–8°C 
(protected from light). Immediately following this, the cells were 
harvested by centrifugation (250 × g for 7 min), the supernatant 
was carefully removed and the pellet washed in 10 mL PBS. This 
was followed by re-pelleting and further resuspension in 1 mL PBS 
prior to being directly transferred into 5 mL BD Flow Tubes (pro-
tected from light). A portion of the cells was analysed by FCM (BD 
FACS Aria I) daily for four additional experimental days following 
the determination of spontaneous background mutant frequencies 
on Day 0. Mutant phenotype gating was subsequently undertaken 
following the use of an unstained instrument calibration standard 
in order to establish an autofluorescence level within the channel 
and hence set the detector voltages correctly to enable a fluores-
cence threshold value of negativity. Once established, subsequent 
stained samples were able to be accurately assessed for the report-
ing fluorophore of GPI-anchored protein (AP) status.
Investigations of FCM defined PIG-A phenotypes 
within TK6 cell populations
Aerolysin permeabilisation
First, 2 µM pro-aerolysin (AeroHead Scientific, Saskatoon, Canada) 
was activated with 2 µg/mL trypsin (diluted in 25 µg/mL Tris pH 8 
buffer) in a 1:1 solution to produce a 250 nM aerolysin solution. 
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Then, parental TK6 PIG-A wild type and PIG-A mutant popu-
lations (isolated by FACS) were adjusted to 2  ×  105 cells/mL in 
RPMI 1640 and treated with a range of aerolysin concentrations 
(15.625–250 nM) in RPMI 1640. After 48 h, 150 µL cell cultures 
were removed from each well and viability assessed using FCM and 
propidium iodide (PI) DNA staining: viable cells are PI-negative, 
and permeabilised non-viable cells are PI-positive; PI was detected 
by increased fluorescence in the FL3-H detector on the FACSCalibur 
(Cell Quest Pro version 5.2.1).
Cell viability assessment
First, 106 untreated TK6 cells, clonally enriched for the CD59 surface 
marker, were resuspended in 50 µL of fresh culture medium and then 
incubated with 20 µL (0.1 mg/mL) of anti-human CD59 R-PE anti-
body for 20–30 min at 2–8°C (protected from light). Immediately fol-
lowing this, cells were harvested by centrifugation (250 × g for 7 min), 
the supernatant was removed and the pellet washed in 2 mL PBS to 
remove residual unbound antibody. Simultaneous to the washing steps, 
1X Annexin V-binding buffer was prepared in deionised water (dH20) 
and placed on ice to cool. Following a second 2mL PBS wash, cells 
were resuspended in 2 mL 1X Annexin V-binding buffer, centrifuged 
and resuspended in an additional 100 µL of the 1X Annexin V-binding 
buffer. Then, 5 μL of Alexa Fluor® 488 Annexin V conjugate was 
added to the 100 µL cell suspension and incubated at room temperature 
for 15 min, protected from light. Post incubation, 2 mL 1X Annexin-
binding buffer was added to each sample, centrifuged (250  × g for 
7 min) and resuspended in a further 200 µL of 1X Annexin-binding 
buffer. Finally, 5 µL (0.25 μg) of 7-aminoactinomycin D (7-AAD) solu-
tion was added to each sample, incubated for a minimum 15 min on 
ice and subsequently diluted via the addition of 1–2 mL of PBS and 
transferred directly into 5 mL BD Flow Tubes, protected from light, 
and analysed within 4 h of initial antibody treatment.
GPI-AP candidate trials in different human cell lines
Fluorescent aerolysin
Prior to use, 1 mL of PBS was added to 25 μg of powdered (lyoph-
ilised) fluorescent aerolysin (FLAER); this stock solution was further 
diluted 1 in 10 (dH20) and 50 μL volumes aliquotted into 0.5 mL 
microcentrifuge tubes for long-term storage (wrapped aluminium 
foil, −20°C). Samples for each cell line, containing 106 cells in sus-
pension, were transferred into sterile 15 mL plastic disposable tubes, 
centrifuged (250 × g for 7 min) and resuspended in 100 μL of fresh 
pre-warmed culture medium (see Cell culture). Cell pellets were care-
fully redispersed and treated with 5 μL of FLAER (in triplicate) at 
3 concentrations; 1×, 0.5× and 0.1× in 2% bovine serum albumin 
(BSA)/PBS. Each tube was incubated for 15 min at room temperature 
and protected from direct light at all times. Post incubation, samples 
were centrifuged, washed with 10 mL PBS and resuspended within a 
further 1 mL of PBS. All samples were placed on ice and protected 
from direct light to maintain the stability of the suspensions and the 
fluorophores used, prior to flow cytometer acquisition.
CD48–B-Lymphocyte Activation Marker 1 and CD55/59 
staining protocol
Samples for each cell line (106 cells) were pelleted and resuspended in 
fresh medium (100 µL) and fluorescently labelled with either 20 μL 
of mouse anti-human anti-CD48 R-PE antibody (cat no.  552855, 
BD Biosciences, Hertfordshire, UK) or with 20 μL of mouse anti-
human anti-CD55 R-PE antibody and 20 μL of mouse anti-human 
anti-CD59 R-PE antibody (room temperature, protected from direct 
light, 30 min). The cells were pelleted (250 × g for 7 min), washed in 
2 mL PBS and resuspended in a further 1 mL PBS and placed on ice, 
protected from light, prior to flow cytometer analysis.
Viability assessment of MCL-5 Cells to avoid 
potential Artefacts
First, 100 μL of 1 μM Staurosporine solution was added to six sepa-
rate MCL-5 cellular suspensions (4 × 106 cells in 10 mL) and incu-
bated for either 30 min, 1 h, 2 h, 3 h, 4 h or 8 h at 37°C. Cells were 
pelleted (250 × g for 7 min), washed twice in 10 mL PBS and resus-
pended in a further 10 mL of fresh medium. Following each treat-
ment, cellular densities were determined, and three further cellular 
samples were constructed each containing 106 cells. The samples were 
then stained with anti-human anti-CD55 R-PE, CD59 R-PE, 7-AAD 
and Annexin V in an analogous protocol to that as described above.
Determination of PIG-A mutant frequency using the 
CD59 phenotypic marker, viability assessment and 
HLA-DR staining within MCL-5 cells
MCL-5 cellular cultures were established from previously cryo-
preserved parental stocks. Cultures were exposed to either EMS 
(0–161.1 µM), N-methyl-N-nitrosourea (MNU; 0–80.5  µM), 
N-ethyl-N-nitrosourea (ENU; 0–322.2  µM) or 2,4 dinitrophenol 
(2,4 DNP; 0–325.9 µM) with DMSO being utilised and as a vehi-
cle control for 24  h. Following treatment, cultures were washed 
(10 mL PBS), counted, seeded (for subsequently daily analysis) and 
106 cellular samples stained ready for initial flow cytometric analy-
sis; 20 µL anti-human anti-CD59 R-PE, 40 μL HLA-DR FITC (cat 
no. 555871, BD Biosciences, Hertfordshire, UK) and 10 μL 7-AAD 
were used in an analogous fashion to previous protocols. Flow cyto-
metric acquisition (FACSCalibur (Cell Quest Pro version 5.2.1)) was 
performed within an hour of sample preparation, and samples were 
stored on ice protected from direct light beforehand. The experiment 
was carried out daily for four additional days following the determi-
nation of the spontaneous background mutant frequencies on Day 0.
Tandem GPI-AP confocal expression analysis in 
MCL-5 cells
Untreated MCL-5 cells (106) were stained with 20  µL anti-human 
anti-CD55 and/or 20  µL CD59 R-PE fluorescent antibodies for 
30 min, washed twice in 3 mL pre-warmed (37°C) PBS and resus-
pended and fixed in 1 mL of 4% PBS-buffered paraformaldehyde for 
15  min at 37°C, before being washed twice more with 3  mL PBS. 
Coverslips, precision 0.17  mm thickness, (cat no.  474030–9000, 
Carl-Zeiss, Hertfordshire, UK) were placed in a 0.1-mL aliquot of 
1mg/mL aqueous poly-l-lysine (Sigma-Aldrich, Gillingham, UK) on 
parafilm, incubated for 10 min at room temperature, washed thor-
oughly using dH20 and left to air-dry. Coverslips were then incu-
bated in excess 1% BSA (Sigma-Aldrich, Gillingham, UK) PBS for 
at least 1 h, washed and placed into 6-well plates (Greiner Bio-One, 
Hertfordshire, UK). Three millilitre of stained cell suspension, at a 
suitable concentration to provide sufficient coverage ~105–106 cells/
mL, was added to each well to enable cellular adhesion and incubated 
for 10  min at room temperature, protected from light. Following 
incubation, each coverslip was microscopically inspected to ensure 
that attachment was successful before being further washed in 3 mL 
PBS and carefully touch dried. Coverslips were then mounted within 
1,4-diazabicyclo[2,2,2]octane (DABCO) (cat no. D27802, Sigma 
Aldrich, Gillingham, UK); 45 mL glycerol (G55-16 100 mL, Sigma 
Aldrich, Gillingham, UK), 2.5  mL Tris-hydrochloric acid buffer 
(pH 8)  and 2.5 mL dH20. Polished glass slides (cat no. 11562203, 
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Fisher Scientific, Loughborough, UK) with autoclave tape were used to 
construct posts, which loaded coverslips were laid down onto 50 μL 
DABCO, centrally between the two posts. Confocal microscopy was 
carried out using an LSM-710 laser scanning confocal microscope and 
supplied ZEN software version 2009 in conjunction with either a 40× 
or 63× oil immersion DIC objective (Carl Zeiss, Cambridge, UK).
Gating strategy investigations
First,106 untreated MCL-5 cells were stained with 20 µL anti-CD55/
CD59 R-PE antibodies and washed (3 mL PBS) prior to flow cyto-
metric analysis, as described previously. Samples were run/tested in 
triplicate utilising the different proposed gating strategies; typically 
FSC-A and SSC-A scatter plots were utilised to define a typically ‘sin-
gle-cell’ population, from these outputs, i.e. 2-D histograms and 2-D 
density scatter plots were constructed utilising the FL-W measure 
of the fluorophore channel (PE) as well as the FSC-W, as proposed 
measures of particle size. Gates were drawn, which encompassed 
at least 90% of the parental population, to further isolate particles 
defined ‘single cell’ in nature and finalised outputs were commented 
in terms of numbers/percentage of single cell CD55/59-positive phe-
notypic PIG-A mutant events, as described above. All these param-
eters were managed using the FACS Diva™ 6 software, and doublet 
discrimination plots were removed to enable easier visualisation of 
results.
In addition, MCL-5 cellular cultures were established from previ-
ously cryopreserved parental stocks. Cultures were exposed to MNU 
(0–1 µg/mL) with DMSO being utilised and as a vehicle control for 
24 h. Following treatment, cultures were washed (10 mL PBS), densi-
ties defined, seeded (for subsequently daily analysis) and 106 cellular 
samples stained ready for initial flow cytometric analysis; anti-human 
anti-CD59 and anti CD55 R-PE, Annexin V and 7-AAD were used in 
an analogous fashion to previous protocols. Flow cytometric acqui-
sition was undertaken on a BD FACSAria 1 (FACSDiva™ 6)  and 
performed within an hour of sample preparation, and samples were 
stored on ice protected from direct light beforehand.
Results and Discussion
Enrichment strategies to optimise CD59 expression 
within TK6 cells
Immunofluorescence antibodies to a number of GPI-anchored surface 
antigens (CD48 and CD59, see Supplementary figure 1, available at 
Mutagenesis Online) revealed that the parental TK6 cell line comprises 
a heterogeneous population, with a significant minority of cells GPI-
anchored protein deficient. Mutagenicity is measured as an increase 
over the spontaneous (pre-existing) background of mutant cells, so a 
high background poses a significant barrier to the development of an 
assay to detect rare mutation events. Consequently, strategies to deplete 
parental TK6 cultures of the presumptive, pre-existing mutant popula-
tions are required (50). The regulatory accepted MLA and HPRT in 
vitro mammalian gene mutation assays have analogous requirement to 
purify the pretest cell cultures of mutants and subsequently enrich for 
wild-type cells. However, a different strategy was required for analy-
sis of PIG-A; three approaches were assessed, immunomagnetic bead 
separation (Dynabead®), which is already used to increase statistical 
power in the in vivo Pig-a assay (29), clonal expansion and FACS. Each 
method was compared for its ability to produce near-homogenous cell 
populations with low phenotypic PIG-A mutant prevalence.
All three enrichment methods reproducibly demonstrated >90% 
homogeneous GPI-AP (CD59)-positive populations (Table  1). 
Table 1. Phenotypic PIG-A assessment of TK6 populations following enrichment
Sample ID Number of total events CD59-positive (%) CD59-negative (%) SD
Dynabead 1a 8216 84.1 15.9
1b 8461 84.3 15.7
1c 8379 84.5 15.5
2 11388 96.5 3.5
3 10000 95.9 4.1
Average 9288.8 89.1 10.9 6.5
Clonal Expansion 1 9427 99.8 0.2
2 10170 84.5 15.5
3 9767 54.7 45.3
4 9836 99.7 0.3
5 10080 28.0 72.0
6 9679 61.8 38.2
7 9708 54.4 45.6
8 10443 83.8 16.2
Average 9888.8 70.8 29.2 25.3
FACS 1a 9480 95.5 4.5
1b 9467 96.2 3.8
1c 9337 95.6 4.4
2a 9867 97.7 2.3
2b 10179 95.9 4.1
2c 10194 87.6 12.4
3a 10900 96.1 3.9
3b 9919 96.5 3.5
3c 9787 96.3 3.7
Average 9903.3 95.3 4.7 3.0
Anti-CD59 R-PE antibody utilised in conjunction with flow cytometry to assess GPI-AP percentage expression within Dynabead®, Clonal Expansion and FACS-
enriched populations of cells (~10 000 single cellular events captured).
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FACS produced the optimum results in terms of average CD59 wild-
type enrichment, 95.3% ± 3.0, with Dynabead® and Clonal expansion 
yielding 89.1% ± 6.5 and 70.8% ± 25.3 CD59-positive cell cultures 
respectively. In terms of reproducibility, FACS and Dynabead® were 
shown to be the most robust methodologies, with clonal expansion 
resulting in a much greater range of purities post enrichment as empha-
sised by the elevated spread of data around the mean. Clonal expansion 
did however result in the optimum individual enrichment purity, with 
99.8% of the subsequent population positive for CD59 expression.
Within the three trialled methodologies, Dynabead® and FACS were 
demonstrated to be highly robust, reproducible methods; however, 
they lacked the refinement to achieve the prerequisite sensitivity. 
In the case of Dynabeads®, the technology favours the use of anti-
gens with larger molecular weights and FACS, especially prevalent 
within older cell sorters, is highly dependent upon operator abil-
ity, machine usage and cellular viability. Even though clonal expan-
sion was demonstrated the most inconsistent in terms of enrichment 
efficiency, the method generated the optimum enrichment yield 
(99.8%)—the lowest background phenotypic PIG-A mutant fre-
quency (~2000 × 106) and was therefore used for preliminary proof 
of principle experiments.
Determination of PIG-A mutant frequency using the 
CD59 phenotypic marker following exposure to the 
potent mutagen EMS
In order to assess the sensitivity of the proposed assay design, the 
performance of CD59 as a phenotypic reporter for PIG-A mutation 
was evaluated in clonally enriched TK6 cell cultures (TK6CD59+) 
exposed to a low-dose range of EMS (Figure 1).
A statistically significant increase in the frequency of cells nega-
tive for CD59 staining at Day 4 of analysis was observed with a 
6-fold increase compared with concurrent controls (P  <  0.01, 
Dunnett’s test). Prior to Day 4 analysis, there were no statistically 
significant increases in CD59-negative cells at any dose, providing 
evidence for a time-dependent induction of the mutant phenotype, 
apparently consistent with mutation induction. The lowest observed 
genotoxic effect level was defined as 10 µg/mL, with minimal cyto-
toxicity observed [~80% relative population doubling (RPD)] at the 
top dose.
Mathematical modelling (PROAST38.9 software) was used to 
further characterise the phenotypic PIG-A mutant dose response 
with EMS. Benchmark dose BMD10 and BMDL10 values (51) of 0.673 
and 0.503 µg/mL, respectively, were observed with comparable BMD 
values for EMS to those reported by Doak et al. (52) in the HPRT cell 
mutation assay (53). However, because the spontaneous phenotypic 
mutant frequency (~0.2%) in controls was high, additional stud-
ies were conducted to further investigate the relationship between 
the absence of extracellular GPI-AP staining and PIG-A mutation 
(Supplementary Figures 2 and 3, available at Mutagenesis Online).
Investigations of FCM defined PIG-A phenotypes 
within TK6 cell populations
Aerolysin permeabilisation has previously been reported as a means 
to confirm a Pig-a mutant phenotype (15,17,54). Aerolysin is a 
Figure 1. Human lymphoblastoid cells (TK6) following 24 h EMS exposure, CD59 antigen utilised as phenotypic PIG-A marker. Day 1–4 frequencies of PIG-A 
mutant TK6 cells (clonally selected) following 24 h low-dose EMS exposure—CD59 antigen utilised as reporter of mutation (Dunnett’s test; *P < 0.05; n = 3, error 
bars ±1 SD; 0.1% PIG-A mutants = 1 mutant × 10–3 cells).
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bacterial toxin secreted by Aeromonas hydrophila, which causes 
GPI-anchor–dependent cell lysis (54–56). Therefore, aerolysin is a 
GPI-anchor–specific toxin that can be used to demonstrate PIG-A 
mutant cell resistance.
When the parental CD59 heterogeneous TK6 cell line was treated 
with aerolysin and stained with the vital dye, PI, the viable cell popula-
tion (PI-negative) is reflected in the frequency of cells that are negative 
for CD59 staining (Figure 2A). Aerolysin treatment of FACS-enriched 
CD59-positive cell cultures (i.e. presumptive PIG-A wild type) were 
predominantly PI-positive (Figure 2B), consistent with aerolysin per-
meabilisation at the GPI-anchor sites causing complete cell death. 
In contrast, aerolysin treatment of cell cultures derived from CD59-
negative cells (i.e. presumptive PIG-A mutants) displayed negligible 
PI staining (Figure 2C), consistent with the absence of GPI-anchor 
sites expected of the PIG-A mutant phenotype.
From these studies, aerolysin treatment can also provide a means 
to directly select GPI-AP deficient cell clones and in turn, sufficient 
biological material for genomic sequencing of presumed PIG-A 
mutants (15,32,49,57).
Lack of cellular membrane integrity, characterised by the initial 
loss of membrane asymmetry, blebbing and the eventual formation 
of pyknotic bodies, is typically observed during mid-late stage apop-
tosis and subsequent cell death (58–60). Due to the extracellular 
localisation of GPI-AP, potential membrane alterations/inversion 
overserved during loss of membrane integrity could induce a mis-
leading PIG-A mutant phenotype and hence, misleading conclusions 
regarding mutagenicity.
To further characterise putative phenotypic PIG-A mutants, cells 
were stained with Annexin V Alexa Fluor 488 and 7-AAD to deter-
mine cell membrane integrity and apoptosis status (phosphatidyl ser-
ine presence). Of the TK6CD59+ cells (97.6%), 10.4% were Annexin 
V-positive (apoptotic) and 2.1% were 7-AAD-positive (lack of cellu-
lar membrane integrity). The small (~2%) CD59-negative cell popu-
lation (i.e. phenotypic PIG-A mutants) showed much higher levels 
of apoptosis or loss of cellular membrane integrity (36.4 and 39.2%, 
respectively (Figure 3). Additional sampling, i.e. extended event cap-
ture, n = 500 000 events, confirmed this observation (Supplementary 
Figure 4, available at Mutagenesis Online).
These data suggest an uneven distribution of viable cells within 
the CD59-positive and CD59-negative cell populations, i.e. between 
the putative phenotypic PIG-A wild-type and mutant populations. 
Moreover, the high prevalence of non-viable cells in the CD59-
negative cell population challenges the previous assumptions made 
about the frequency of presumptive PIG-A mutants. This could 
result in artefact, leading to elevated background frequencies of 
putative PIG-A mutants and a masking consequence if not fully 
removed from analysis; the overall effect could greatly decrease 
assay sensitivity (61).
GPI-AP candidate trials in different human cell lines
The establishment of a promising assay design within TK6 cells led 
to the identification of a potential misinterpretation of phenotypic 
PIG-A mutant frequencies. In an attempt to alleviate the viability 
issue and hence, remove potential preparative stages that could 
influence viability, additional cell line and reporter phenotypic com-
binations were assessed in order to identify an unenriched low prev-
alence of spontaneous PIG-A mutants. The variability, in terms of 
surface antigen expression, between the different candidate human 
B-lymphoblastoid cell lines being considered for assay development 
were evaluated. Immunofluorescence staining was used to assess the 
expression of several well-characterised cellular surface antigens or 
the GPI-anchor status of the cell type, i.e. FLAER, B-lymphocyte 
activation marker [(BLAST-1)/(CD48)], protectin (CD59) and 
decay-accelerating factor (DAF/CD55).
FLAER is a fluorescently modified version of inactive aerolysin, 
retaining high affinity for GPI-AP moiety binding. Due to its com-
prehensive binding, FLAER was investigated for its use as a generic 
reporter for PIG-A mutation detection. CD48 was chosen for its 
GPI-AP characteristics and routine use as a B-lymphocyte activation 
marker (BLAST-1).
Low passage TK6 cells were shown to stain poorly for all four 
cell surface antigen candidates, with only 5.9% cells positive for 
FLAER (at top concentration 2.5  µg/mL), 2.2% cells positive for 
CD48 expression and 62.6% cells positive for CD55 and CD59 
expression (Figure 4). The AHH-1 cell line showed higher levels of 
staining, i.e. 75.2% cells were positive for FLAER staining, 83.5% 
cells positive for CD48 staining and 99.2% cells positive for CD55 
and CD59 expression (Figure 4). MCL-5 exhibited the most compre-
hensive staining for all fout candidates, i.e. 93.5% cells positive for 
FLAER, 92.1% cells positive for CD48 and 99.8% cells positive for 
CD55 and CD59 (Figure 4).
The background levels of CD55 and CD59 expression in MCL-5 
cells were similar to those of the original TK6 cell lines used follow-
ing enrichment (TK6CD59+/CD55+). Given these fundamental properties 
Figure  2. FCM analysis of human lymphoblastoid cells (TK6) following 
aerolysin and PI treatment. Flow cytometric outputs following consecutive 
aerolysin and PI treatment on parental TK6 strain (A) and FACS enriched 
CD59 positive (B) and negative populations (C).
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and the potential for artefact induction following a loss in viabil-
ity during enrichment, MCL-5 cells were chosen for the continuing 
development of the in vitro PIG-A assay.
Viability assessment of MCL-5 Cells to avoid 
potential artefacts
P53 status and, hence, apoptosis functionality has been a debated 
topic in regard to the cell lines utilised within in vitro genetic toxi-
cology testing (62,63). Therefore, prior to PIG-A assessment, a more 
detailed viability assessment was undertaken to establish apoptosis 
capability and provide evidence for p53 functionality. In previous 
TK6 cell experiments, a high prevalence of non-viable cells (apop-
totic or necrotic) had been observed in the CD59-negative cell popu-
lations, which could confound an accurate estimate of the PIG-A 
mutant phenotype. Therefore, the impact of apoptosis on cell surface 
antigen expression in MCL-5 cells was assessed using cells treated 
with the apoptosis inducer staurosporine.
Cell viability was assessed at various time points using flow 
cytometric light scatter properties together with GPI-AP label-
ling and Annexin V and 7-AAD staining. Following staurosporine 
treatment, there was a dose- and time-dependent increase in the 
frequency of apoptotic cells and loss of cellular membrane integ-
rity (Supplementary Figure  5, available at Mutagenesis Online); 
although at the earlier stages there was no significant change in cell 
morphology by FCM (determined by forward and side scatter pro-
files). Significantly, a corresponding decrease in GPI-AP expression 
(Figure 5) was also observed, with top doses seemingly inducing phe-
notypic PIG-A mutant events (Table 2).
Since the previous observations in TK6 cells were also seen with 
MCL-5 cells, there is clearly the potential for cell viability artefacts 
to confound the PIG-A mutation phenotype assessment. It is there-
fore critical that viability dyes (both apoptosis and cell death) and 
accurate/reproducible FCM gating are applied in the development 
and assessment of in vitro PIG-A assays.
Determination of PIG-A mutant frequency using the 
CD59 phenotypic marker, viability assessment and 
HLA-DR staining within MCL-5 cells
To evaluate the possible benefit in phenotypic PIG-A mutation detec-
tion accuracy, transmembranous membrane protein marker staining 
was trialled to more accurately exclude non-viable events from FCM 
analysis. HLA-DR was chosen as a trial membrane marker for its 
comprehensive expression within the cell line utilised and to provide 
additional confidence in phenotypic identity. To investigate the util-
ity of MCL-5 cells in the in vitro PIG-A assay, cell cultures were 
exposed to three alkylating agents, as positive mutagens, i.e. EMS, 
Figure 4. Average cellular surface marker expression within AHH-1, MCL-5 and low passage TK6 cells. FLAER–Alexa Fluor 488™ conjugate, CD48 phycoerythrin 
conjugate and CD55/59 phycoerythrin conjugate fluorescent dyes utilised to estimate surface marker expression. (A) AHH-1, (B) MCL-5 and (C) low passage TK6 
cells (~10 000 single cellular events; n = 3, error bars ±1 SD).
Figure 3. Preliminary validation of presumed phenotypic PIG-A mutant TK6 cells using flow cytometry. Viability assessment of clonally enriched CD59-R-PE–
stained untreated TK6 cells (A) PIG-A mutant phenotype assessment, (B—I, II) viability dot plot, (C—I, II) apoptosis measure (Annexin V) and (D—I, II) loss of 
membrane integrity (7-AAD; ~10 000 single cellular events), PIG-A mutant phenotype and PIG-A wild-type cytograms denoted by I and II, respectively. P gates 
defined from maximum auto fluorescence observed following instrument calibration standard analysis within the respective channel.
8 B. J. Rees et al.
 at Sw
ansea U
niversity on January 11, 2017
http://m
utage.oxfordjournals.org/
D
ow
nloaded from
 
MNU or ENU and as a negative control, 2,4 DNP. Following 24 h 
treatment, cells were harvested and subject to daily modified cell 
staining including anti-HLA-DR (membrane integrity), 7-AAD and 
anti-CD59 to determine PIG-A phenotype (Figure 6).
Acute MNU exposure resulted in a dose-dependent increase in 
the frequency of viable CD59-negative MCL-5 cells, i.e. mutant 
PIG-A phenotype, from 1.01% to 6.43% at the top concentration 
tested. Although there was a strong positive correlation between 
dose, cytotoxicity and phenotypic PIG-A mutants, none of the doses 
were statistically significant (P > 0.05). EMS exposure resulted in a 
comparable dose-dependent increase, with the top dose of 161 µM 
(equivalent to ~20 µg/mL) eliciting a statistically significant increase 
(P < 0.05) with a corresponding increase in cytotoxicity [8% relative 
increase in cell count (RICC)]. ENU exposure did not increase the 
number of CD59 negatively stained cells over background, i.e. the 
relative average phenotypic mutant frequency (P > 0.05). However, 
data did appear to be affected by variance between replicates, and 
cytotoxicity again was observed to be elevated. Acute 2,4 DNP expo-
sure resulted in a non-linear Day 4 dose response, with no evidence 
for any correlation between dose and increase in relative PIG-A 
mutant frequency (P > 0.05). Cytotoxicity again was demonstrated 
to be highly dose dependent, with top doses eliciting significantly 
Figure 5. Tracking phenotypic PIG-A status through apoptosis and necrosis. Phenotypic PIG-A mutant frequency data for MCL-5 cells undergoing (A) apoptosis 
and (B) necrosis following a time course acute 1 µM staurosporine exposure: (1) 30 min, (2) 60 min, (3) 120 min, (4) 240 min and (5) 480 min. Relative PE detector 
signals utilised as the measure for surface GPI-AP expression (>3000 events analysed in each sample). ‘PIG-A WT’ gate present defines threshold for phenotypic 
PIG-A mutant status.
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increased cytotoxicity, however, with no corresponding increments 
of PIG-A mutant frequency (as expected).
The data demonstrated the expected EMS and MNU results in 
terms of potency, MNU was observed to induce the larger fold increase 
in CD59-negative cells, over the concurrent controls. However, ENU 
did not induce the expected dose response most likely due to exces-
sive variation within replicates. Utilising significantly shorter assay 
durations (4–5 days) than those recently described in analogous pub-
lications (8–14 days) (50,64) may contribute to the reduced observed 
genotoxic effect of ENU, possibly preventing an adequate time period 
for mutant phenotype manifestation. However, like 2,4 DNP, ENU 
showed little evidence for a positive correlation between cytotoxicity 
and elevated numbers of CD59 negatively stained cells, i.e. phenotypic 
PIG-A mutant frequency. This suggests that the inclusion of membrane 
assurance markers lessened the potential induction of phenotypic PIG-
A mutant mimicking events. 2,4 DNP, a non-genotoxicant, was dem-
onstrated to not increase phenotypic PIG-A mutant frequency across 
the entire dose range, even at doses that elicited severe cytotoxicity.
Tandem GPI-AP confocal expression analysis in 
MCL-5 cells
Limited physiological data, in regard to the Pig-a mechanism, is 
available to describe the nature of extracellular surface protein local-
isation and density on the surface of human lymphoblastoid cells. 
Figure 6. Trialled usage of HLA-DR staining to validate single marker PIG-A dose response data within MCL-5 Cells. Day 4, low passage MCL-5 average relative 
phenotypic PIG-A mutant frequency following 24 h (A) MNU (B) 2,4-DNP, (C) EMS and (D) ENU exposure, CD59 antigen utilised as reporter for mutation, 
inclusion of HLD-DR and 7-AAD staining to ensure cellular membrane integrity (Dunnett’s/Dunns test; *P < 0.05; n = 3; error Bars ±1 SD) PIG-A mutant data 
relative to the percentage of phenotypic PIG-A mutants observed within the concurrent control.
Table 2. Tracking phenotypic PIG-A status through apoptosis and necrosis
Sample identification Necrotic cells Apoptotic cells
Percentage of  
dead cells
CD55/59- 
positive (%)
CD55/59- 
negative (%)
Percentage of  
viable cells
CD55/59- 
positive (%)
CD55/59- 
negative (%)
30 min 27.8 100.0 0 2.3 100.0 0
60 min 43.0 100.0 0 4.4 100.0 0
120 min 24.9 100.0 0 5.2 100.0 0
240 min 61.8 100.0 0 44.2 99.9 0.061
480 min 76.0 98.7 1.3 46.7 99.9 0.108
Phenotypic PIG-A mutant frequency data for MCL-5 cells undergoing (A) apoptosis and (B) necrosis following a time course acute 1 µM staurosporine exposure 
(>3000 events analysed in each sample).
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Within the scope of the PIG-A assay, mutagenesis is indirectly meas-
ured through the presence or the absence of GPI-AP, and therefore, 
mechanistic biological evidence at the cellular level could be used to 
provide increased integrity. Therefore, the localisation, density and 
coverage of initially single and sequentially tandem GPI-AP markers 
were investigated on the surface of MCL-5 cells using high-resolu-
tion confocal image analysis.
The proteins CD58, CD55 and CD59 were identified as possible 
cell surface biomarkers for the PIG-A phenotypic mutation. CD58 is 
a well-characterised GPI-AP, integral in strengthening the interaction 
between T cells and macrophages (65) and is expressed at intermedi-
ate/high levels on most subsets of normal peripheral blood leuco-
cytes (66). CD59 (protectin) and CD55 (DAF) are used routinely for 
clinical diagnostic screening of PNH, associated with PIG-A muta-
tion (19), and CD59 is also used in the in vivo Pig-a assay in rodents 
(29,32,34,67). However, CD58 was later demonstrated to have a 
transmembranous single-pass isoform (65) and therefore, CD59 and 
CD55 were selected for further evaluation in the development of this 
in vitro assay design.
Results indicated that both CD55 and CD59 immunofluores-
cence staining was associated comprehensively with the extracel-
lular membrane localisation (Figure  7 AI and BI) as indicated by 
a distinctive halo image, reflecting the presence of peripheral cell 
staining. Utilsing 3-D reconstructed Z-stacked images, single GPI-AP 
expression was clearly defined as punctate in nature and consisted 
mainly of dense pockets of cell membrane expression (Figure 7 AII 
and BII). CD59 surface antigen expression was estimated to be less 
comprehensive than CD55. There was no clear association/correla-
tion between staining density and distinct morphological features 
in the membrane following the construction of a composite image 
utilising transmitted light (Figure 7 CI). However, tandem labelling 
with the combined CD55/59 generated significantly greater staining 
and surface coverage (Figure  7 CII); and although the antibodies 
were still localised to densely staining regions, a much larger propor-
tion of the extracellular membrane was visible. The punctate nature 
of staining was identified as a potenital limiting factor when utilsing 
specific excitatory sources and subsquent fluorescent image capture 
sysytems.
Utilsing CD55/59 tandem labelling to determine PIG-A pheno-
type facilitates greater confidence in the definition of presumptive 
PIG-A mutant cells. The unlikely probability of losing both surface 
antigen signals through a non-mutagenic mechanism during analysis 
significantly reduces the likelihood of misleading results when com-
bined with appropriate cell viability labelling. In addition, due to the 
punctate nature of GPI-AP association with the surface membrane, 
and the nature of laser light excitation and recording, specific laser 
Figure 7. GPI-AP surface expression analysis within MCL-5 cells. Utilising either or both anti-CD55 R-PE/CD59 R-PE treated 4% PFA fixed MCL-5 cells, confocal 
microscopy images were generated under the 63X oil immersion objective. High resolution images were produced and displayed within a 3-D reconstruction 
following 1024 × 1024, z-stack capture utilising the laser scanning confocal microscope. Detected, R-PE signal was retrospectively artificially coloured for image 
clarity and cohesion (scale bar 50 µM).
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platforms could suffer from a bias due to the plane of light excitation 
and hence surface marker exposure.
Gating strategy investigations
Assay refinement and cell line alterations have led to the develop-
ment of an in vitro PIG-A assay design utilising: (i) a membrane 
assurance marker (HLA-DR); (ii) viability markers (Annexin V and 
7-AAD) and (iii), tandem antibody reporting markers (CD55/59). 
However, gating strategy also contributes significantly to the per-
formance of the analysis. The use of alternative properties of the 
recorded light signal, other than solely the average or maximum 
fluorescence value generated, was investigated to more accurately 
Figure 8. Establishment of a robust in vitro PIG-A assay gating strategy. Utilising viability dye incorporation (Annexin V and 7-AAD) and tandem markers (CD55 and 
CD59) the proposed robust reproducible gating strategy (B) was directly compared against traditional flow cytometry gating (A). Retrospectively, Day 3, 24 h MNU 
(0–1 µg/mL) exposure data within MCL-5 cells was assessed using both methods in order to estimate phenotypic PIG-A mutant frequency and hence, dose response.
Table  3. Summary of presumed phenotypic PIG-A status of parental untreated MCL-5 cells, pre-enrichment utilising different gating 
strategies.
Sample ID Number of recorded events Single-cell events Trialled gated events Number of viable cells CD55/59-positive (%)
Instrument calibration standard 43 856 20 575 17 574 17 573 0
Original gating 48 629 20 569 n/a 17 577 85.45
Trialled gating 1
 FSC-A vs PE-W 1 48 629 20 391 18 056 17 874 99.99
 FSC-A vs PE-W 2 59 135 20 495 17 983 17 750 99.99
 FSC-A vs PE-W 3 48 190 20 418 18 171 18 019 100.00
 Average 51984.7 20 434.7 18 070 17 881 99.99
Trialled gating 2
 PE-A vs PE-W 1 48 629 20 841 18 584 18 407 100.00
 PE-A vs PE-W 2 59 135 20 882 18 384 18 140 100.00
 PE-A vs PE-W 3 48 190 20 748 18 431 18 245 100.00
 Average 51984.7 20823.7 18466.3 18 264 100.00
Tandem surface antigen markers CD55 and CD59 were utilised as indirect reporters of PIG-A mutation in order to assess phenotypic PIG-A mutant status 
following incorporation of pulse width measurement gating strategies (>20 000 defined single cellular events were captured).
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define a viable single-cell population in which to assess PIG-A phe-
notype. Fluorescence width measurements (time of flight) have been 
recently incorporated into FCM analysis as an additional variable to 
be used to estimate cell size and therefore, offer a potential supple-
mentary layer of cell characterisation during analysis.
Following the trialling of three gating strategies (Table 3), each 
utilising a different combination of fluorescence area and width 
measurements to define the single-cell population; it was apparent 
that the strategy had significant implications on the final presumptive 
PIG-A mutant frequency. Utilising pulse width measurements, analo-
gous to that observed within a typical doublet discriminant plot, as 
an additional means to classify particles as single cell in nature could 
significantly reduce the number of events falsely being defined as sin-
gle cell and therefore more accurately define the phenotypic PIG-A 
mutant frequency. Utilising a retrospective analysis on singlet Day 3, 
24-h MNU exposure data within MCL-5 cells (Figure 8), more realis-
tic mutant frequency data (~100 phenotypic mutants per 1 × 106 cells 
scored) was generated following the implementation of the refined 
gating strategy. However, pulse width measurements in combination 
with area measures for the fluorophore reporting phenotypic PIG-A 
status can have a biasing effect on mutant gating, when restrictive 
region gates were applied to the fluorescence area axis. This gating 
combination underestimated the number of defined phenotypic PIG-
A mutant cells, unless gating counter measures were used.
FCM analysis can be subjective without the use of standardised 
protocols. Therefore, identifying reproducible methods for establish-
ing thresholds and utilising unbiased gating approaches are funda-
mental in establishing comprehensive test systems with confidence 
and accuracy. Utilising pulse width measures in combination with a 
robust threshold gating strategy could significantly reduce the num-
ber of falsely identified putative phenotypic PIG-A mutant events 
(Figure 8). Doublet discrimination and correct pulse width measures 
more accurately define the viable single-cell population and therefore 
can prevent the inclusion of doublets, underestimating/overestimat-
ing phenotypic mutant frequency, or debris from inducing false posi-
tives. Standardising the gating approaches and further refining assay 
design has been shown to reliably reduce artificially high baseline 
mutant frequencies (~5–50 × 10−6 mutants) and has brought the per-
ceived assay sensitivity more in line with currently validated in vitro 
gene mutation endpoints (MLA/HRPT), enabling future low-dose 
investigations and potential quantitative dose–response modelling.
Conclusions
During this study, the proposed in vitro PIG-A assay design under-
went a number of revisions and refinements following identifica-
tion of potential confounding factors. The assay design, established 
within the metabolically active, genetically modified, human MCL-5 
cell line, has demonstrated proofs of principle and the potential 
focus for future work. Toxicity was demonstrated to be a continuous 
problem associated with the misidentification of the putative PIG-A 
deficient phenotype; however, the studies reported here suggest that 
these issues are effectively addressed through the inclusion of mem-
brane integrity markers such as HLA-DR or alternatively CD19 (50) 
(highlighted by the 2,4-DNP and ENU data sets; Figure 6) in combi-
nation with adequate apoptosis and cell death markers.
Toxicity measures are used to define the doses tested and relevance 
of results within any mutation assay. A measure utilised within the in 
vitro PIG-A assay design which does not account for clonal expansion/
cloning efficiency could miscalculate toxicity. RICC, RPD and relative 
cell counts are all measures that may not be strictly suitable outside of 
intended usage within the MN assay based on the duration of the assay. 
Shifting the toxicity measure more in line with analogous test systems, 
such as HPRT and/or MLA, could potentially alleviate toxicity misin-
terpretation, seemingly more apparent at the initial stages of phenotype 
assessment and could facilitate minimal experimental duration.
The genotype/phenotype relationship validation is still ongoing, 
recent publications reporting novel PIG-L gene mutations, following 
loss of heterozygosity deletions within the TK6 cell line, which also 
contribute to the GPI-AP deficient phenotype in addition to PIG-
A mutations (38,64), have heightened the need for cell line-specific 
identification of additional genes active within the current pheno-
typic PIG-A scoring mechanism. Validatory sequencing experiments 
should not utilise any inadvertently biasing means of loss of pheno-
typic mutant selection if population statistics are to be generated and 
focus on whole genome sequence analysis or at least multiple PIG 
genes from the accurately gated loss of phenotype population.
In conclusion, this study suggests that a stand-alone PIG-A 
assay within MCL-5 cells is more promising than a TK6 cell-based 
assay. Further refinement, followed by a comprehensive assessment 
of specificity, sensitivity and transferability could lead to the estab-
lishment of a high content, high-throughput assay system with the 
potential for use within a screening as well as a regulatory hazard 
and risk assessment environment. All data from which conclusions 
were drawn is contained within the article or clearly referenced.
Supplementary data
Supplementary Figures 1 to 5 are available at Mutagenesis Online.
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